Overview

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

Status:
Recruiting

Trial end date:
2024-10-27

Target enrollment:

Participant gender:

Summary

This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Carboplatin
Paclitaxel